Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00957853 · ClinicalTrials.gov registry record · Phase 2
Preoperative Treatment With Cetuximab and/or IMC-A12
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00957853: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00957853 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00957853, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to give cetuximab and/or IMC-A12 before surgery for squamous cell carcinoma of the head and neck, in order to learn if these study drugs may cause changes in biomarkers. Biomarkers are chemical "markers" in the blood and/or tissue that may be related to a reaction to study treatment. The safety of the study treatments will also be studied.
Interventions
- DRUG Cetuximab
- DRUG IMC-A12
- PROCEDURE Surgical tumor resection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-10-17 |
| Est. Completion | 2018-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00957853
The ClinicalTrials.gov registry entry for NCT00957853 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT00957853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00957853 about?
NCT00957853 is a clinical study titled "Preoperative Treatment With Cetuximab and/or IMC-A12". The goal of this clinical research study is to give cetuximab and/or IMC-A12 before surgery for squamous cell carcinoma of the head and neck, in order to learn if these study drugs may cause changes in biomarkers. Biomarkers are chemical "markers" in the blood and/or tissue that may be related to a ...
What is the current status of trial NCT00957853?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2011-10-17. Estimated completion is 2018-08-15.
What interventions are being tested in trial NCT00957853?
The interventions under investigation include: Cetuximab (DRUG), IMC-A12 (DRUG), Surgical tumor resection (PROCEDURE).
Who is sponsoring clinical trial NCT00957853?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.